Close
Open Nav
2018 Advisory Committee

Kyle Hathaway, PhD, Director of Policy and Government Relations, Asia Pacific, MSD, Merck

Dr. Kyle Hathaway

Bio coming soon. 

Apo Huang, PhD, Secretary General, Taiwan Bio Industry Organization

Apo Huang

After receiving his PhD in Plant Pathology from Rutgers University, New Jersey (USA) in 1977, Dr. Bor-Fuei “Apo” Huang conducted his postdoctoral research at the Fox Chase Cancer Center in Philadelphia (USA). From 1979, he worked in the US as researcher and program directors in various AgBiotech organizations including Boyce Thompson Institute at Cornell University, AgBiotech R&D center at Allied Signal Corp. and Enichem Americas…. In 2002, he moved back to his native country Taiwan to join the Development Center for Biotechnology (DCB) switching from AgBiotech to drug development and from research to business development and management. With increasing responsibility he was the Director of International Collaboration, Director of Business Development and the Director General of Industry Promotion Division with a team of 70+ members conducting industrial information research, tech transfer/licensing and commercialization, business planning and development, private public partnership and international collaboration. After his retirement in 2012, he has been consulting with companies that are interested in developing biotech business with Taiwan. Since 2009 he has been the Secretary General of the Taiwan Bio Industry Organization, the largest biotech Association in Taiwan. He also has an MBA degree from the Pennsylvania State University, USA.

Taro Inaba, Managing Partner, Remiges Ventures

Taro Inaba

Taro has over 25 years of business development and venture investment experience. He spent 13 years at Mitsui Ventures in the venture investment field during which time he led the deal discovery, negotiation and due diligence process for the major portfolio companies in the drug discovery and development area and held positions as a board member in 11 companies. While at Mitsui Ventures he built and managed the biopharma investment team and infrastructure and served as President & CEO from 2008 to 2009. Prior to Mitsui Ventures Taro spent 10 years in various capacities at Mitsui & Co. Ltd, including extensive experience in business development roles. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, MediciNova

Yuchi Iwaki

Dr. Yuichi Iwaki is a founder, president and CEO of Medicinova, Inc, a biopharmaceutical company which is public both in the JASDAQ (code 4875) and NASDAQ (code MNOV) market. Dr. Iwaki also holds three professorships at the University of Southern California, Keck School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. He is also a visiting professor at the Toho University School of Medicine, St. Mary University and Kyushu University in Japan. Prior to joining the faculty at the University of Southern California, Keck School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh, School of Medicine in the Departments of Surgery and Pathology from 1989 through 1992. He received both his M.D. and Ph.D. degrees from Sapporo Medical School Japan. Dr. Iwaki is the author of more than 230 peer-reviewed publications and more than 40 books or book chapters. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a board member of several biotechnology companies.

Ryo Kubota, MD, PhD, Chairman, President, and Chief Executive Officer, Acucela 

Ryo Kubota

Dr. Kubota is Chairman, President, and CEO of Acucela. Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of individuals worldwide. Prior to founding Acucela, Dr. Kubota worked in the ophthalmology field, including serving as a faculty member at both Keio University and the University of Washington School of Medicine. He holds an MD and a PhD in medicine from Keio University. In the course of his work at Keio, Dr. Kubota discovered a glaucoma gene, myocilin, which earned him the Suda Award.

Bo Liu, PhD, Principal, Venture Investments, Johnson & Johnson Development Corporation – JJDC, Inc. (JJDC)

Bo Liu

Dr. Liu is the Principal of Venture Investments of Johnson & Johnson Innovation – JJDC, Inc. (JJDC). He is based in Shanghai, China and focuses on the life science investment opportunities in Asia Pacific regions. Prior to joining JJDC, Bo was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Bo has executed many M&A, licensing and venture investment transactions in the US, Europe and Asia Pacific. Bo received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University.

Arlene Morris, Chief Executive Officer, Willow Advisors

Arlene Morris

Ms. Morris is currently the CEO of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development. Previously she was the CEO and Director of Syndax an oncology/immunoncology company developing entinostat for estrogen receptor positive metastatic breast cancer and lung cancer as well as melanoma. Under her leadership the compound advanced to a Phase 3 NCI sponsored study in combination with exemestane to reverse resistance to hormone therapy in patients. The compound was awarded Breakthrough Status by the FDA. Previously she was the chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates including treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda and an Initial Public Offering and several follow on offerings. Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president of business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. In addition to Syndax, Ms. Morris serves on the board of directors of Neovacs SA, Palatin, Biodel and Dimension Therapeutics. She also serves on the board of the Foundation for Research and Development at the Medical University of South Carolina. She was recently on the boards of the Humane Society of Silicon Valley and BIO.

Kyle Murphy, Managing Director and Founder, KMG Japan

Kyle Murphy

Kyle E. Murphy is the Managing Director and Founder of KMG Japan. Kyle has lived in Japan for a significant portion of his adult life. His business has involved working with Japanese and Asian Life Science and healthcare businesses for over 30 years. Kyle speaks Japanese and built a strong network of contacts in both the healthcare industry and government administration. He has represented over 100 clients and successfully structured numerous alliances between Japanese, Asian and foreign companies. Prior to founding KMG Japan, Kyle served as the First Commercial Secretary in the US Embassy in Tokyo where he managed all trade negotiations and activities related to bringing US companies into the Japanese healthcare market. Kyle began his career in the healthcare industry with business development and marketing positions at Schering-Plough in Osaka, Japan and SmithKline in the US.

BT Slingsby, MD, PhD, MPH, Chief Executive Officer and Executive Director, Global Health Innovative Technology Fund

BT Slingsby

Dr. Slingsby is CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund. Previously, he was the global head for access strategies at Eisai Co., Ltd. where he developed new business models for R&D and overlooked market access in the developing world. Dr. Slingsby has helped launch numerous start-ups in Japan and the U.S., and currently advises at the Graduate School of Medicine at the University of Tokyo and Kyoto University. He sits on the Public-Private Partnership Forum at the Institute of Medicine in the U.S., and has published over 50 peer-reviewed articles on medicine and public health in both Japanese and American literature. Dr. Slingsby graduated with honors from Brown University, earned Master’s and Doctorate degrees from Kyoto University and the University of Tokyo, and received his Medical Doctorate from the George Washington University. He is a former professional triathlete and member of the U.S. World Cup Team.

Charles Stacey, MD, Chief Executive Officer, Accera

Charles Stacey

Dr. Stacey has over 15 years of experience in healthcare; working as a healthcare provider, executive, entrepreneur and investor. Prior to joining Accera, he was with Inventages, a global healthcare venture capital and private equity group. Dr. Stacey received his medical degree from King’s College London and practiced as a reconstructive surgeon. His undergraduate degree and basic research were in the neurosciences at University College London. Dr. Stacey also completed an MBA at the London Business School and the Wharton School.

Ted Tanaka, Partnering Consultant, Tanaka International LLC

Ted Tanaka

Ted Tanaka has worked at Accenture, where he managed teams of Accenture consultants and client staff to design and install improved management information systems for major US and Japan clients (including Yamaha & Ricoh). After 11 years, Los Angeles’ Consulting Division had grown to 170 consultants. In 1986, Accenture, he created Tanaka International, an industry leading Japan/Asia specialist to clients in the USA, Canada, UK and Australia which aims to form corporate strategic alliances. He has personally arranged and conducted more than 2,500 strategic alliance and licensing meetings for clients at the global headquarters of Japan’s largest drug manufacturers. He maintains personal, direct contact with Japanese CEOs, board of directors and global licensing heads, and has assisted clients to sign 23 license agreements to-date in Japan and Korea.

Gil Van Bokkelen, PhD, Chairman and Chief Executive Officer, Athersys

Gil Van Bokkelen

Dr. Van Bokkelen has served as Athersys Chief Executive Officer and Chairman since August 2000. Dr. Van Bokkelen co-founded Athersys in 1995 and has served as Chief Executive Officer and Director since the Company’s founding. Prior to May 2006, he also served as the Company’s President. Dr. Van Bokkelen is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine.  He served as the Chairman of the Alliance for Regenerative Medicine from 2010 through 2012, a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine, and served ex officiofrom 2013 to 2014. He has served on a number of other boards, including the Biotechnology Industry Organization’s ECS board of directors (from 2001 to 2004, and from 2008 to present). He received his Ph.D. in Genetics from Stanford University School of Medicine, his B.A. in Economics from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of California at Berkeley.